ESR2 and non-small cell lung carcinoma: We also demonstrate the metastatic malignant properties of two NSCLC cells which was treated with estradiol (E2), the ERα-selective agonist PPT, the ERβ-selective agonist DPN and the ER antagonist fulvestrant, ERβ-Knockdown or ERβ-Overexpressed.